## Medication Reconciliation and Polypharmacy Work Group Technology & Innovation Sub-committee

## **Meeting Minutes**

MEETING DATE	MEETING TIME	Location
January 14, 2019	3:00рм – 4:00рм	https://zoom.us/j/153975347

SUB-COMMITTEE MEMBERS	-COMMITTEE MEMBERS						
Bruce Metz (Chair)	x	Nitu Kashyap	x	Samantha Pitts (JHMI)	х		
Thomas Agresta	x	Jennifer Osowiecki	x	Stacy Ward-Charlerie (Suresciprts)	х		
Sean Jeffery	х	Jake Star (VNA)		Marie Renauer (YNNH)	х		
SUPPORTING LEADERSHIP							
Allan Hackney (OHS)	x	Michael Matthews (CedarBridge)	x	Kate Hayden (UConn Health)	x		
Sarju Shah (OHS)	х	Chris Robinson (CedarBridge)	х	Sabina Sitaru (HIE Entity)	х		

	nutes							
	Торіс	Responsible Party	Time					
L.	Welcome and Call to Order	Sarju Shah	3:00 PM					
	Sarju Shah welcomed the Sub-committee members to the meeting and called the meeting to order. Sarju provided an overview of the agenda.							
	Michael Matthews provided an overview of the Sub-co	ommittee membership. Michael asked	Bruce Metz to					
	confirm that he is volunteering as Chair of the Sub-committee; Bruce confirmed. Bruce said he is excited to get started and to move the charter forward.							
2.	Public Comment	Attendees	3:05 PM					
	There was no public comment.							
3.	Project Charter Review	Michael Matthews	3:10 PM					
	Michael Matthews provided an over of the high-level goals and objectives found within the approved project charter of the Medication Reconciliation and Polypharmacy (MRP) Work Group.							
4.	Sub-committee Discussion	Attendees	3:35 PM					
	Michael Matthews explained that the Sub-committee timeline. The only caveat about timeline is that the MF by the end of June. Each Sub-committee will contribut	RP Work Group recommendations need	d to be finalized					
	timeline. The only caveat about timeline is that the MF by the end of June. Each Sub-committee will contribut	RP Work Group recommendations need	d to be finalized					
	timeline. The only caveat about timeline is that the MR by the end of June. Each Sub-committee will contribut MRP recommendations. Tom Agresta provided an overview of the technology a some topics that the Sub-committee will need to have meaningful recommendations, including the current te reconciliation, as well as any technology that uses more solutions. Tom also thinks it is necessary to understand	RP Work Group recommendations need e one or two building blocks that will in goal considerations. These consideration a basic understanding of in order to de echnology for prescribing, deprescribing dern architecture that has potential for d where innovation is occurring and ho	d to be finalized ofform the over ons represent evelop g, and use in future w the group ca					
	timeline. The only caveat about timeline is that the MR by the end of June. Each Sub-committee will contribut MRP recommendations. Tom Agresta provided an overview of the technology a some topics that the Sub-committee will need to have meaningful recommendations, including the current te reconciliation, as well as any technology that uses more solutions. Tom also thinks it is necessary to understand "skate to where the puck is going to be." Tom added the	RP Work Group recommendations need e one or two building blocks that will in goal considerations. These consideration a basic understanding of in order to de echnology for prescribing, deprescribing dern architecture that has potential for d where innovation is occurring and ho hat this list of considerations is not exh	d to be finalized ofform the over ons represent evelop g, and use in future w the group ca austive.					
	timeline. The only caveat about timeline is that the MR by the end of June. Each Sub-committee will contribut MRP recommendations. Tom Agresta provided an overview of the technology a some topics that the Sub-committee will need to have meaningful recommendations, including the current te reconciliation, as well as any technology that uses more solutions. Tom also thinks it is necessary to understand	RP Work Group recommendations need e one or two building blocks that will in goal considerations. These consideration a basic understanding of in order to de echnology for prescribing, deprescribing dern architecture that has potential for d where innovation is occurring and ho hat this list of considerations is not exh be what areas they are interested in exp interested in learning about what techn readsheet that details who uses the te and the pros and cons. Dr. Phil Smith, an <i>I Wreck</i> that proposed a solution to me	d to be finalize form the over ons represent evelop g, and use in future w the group ca austive. ploring during ologies curren chnology, how invited guest edication					

much like a utility concept. A couple of projects that have caught Phil's attention are InfoSage and the use of kiosks in the Oregon VA system. Nitu Kashyap said that it will be easy to box ourselves into the solutions, and that we should be working backwards once we understand what exists. Stacy Ward-Charlerie said that she is interested in understanding what is currently possible and how data can become actionable in the hands of providers. Marie Renauer said that she is interested in looking at how technology can be leveraged to enable successful medication reconciliation and support the provider process at the point of care. Bruce Metz agreed that understanding what exists today is a foundational element. He is interested in learning what solutions can be effective when delivered on a large scale. Bruce is also interested in learning about the current issues and gaps. Bruce said that our time will be well spent by looking at innovation and the possibility of future solutions, as Connecticut is in a good position to leap frog other states.

Michael asked the group if they have an opinion on whether this group should be looking at the existing technology that can be implemented more effectively, or if it should be looking at longer term solutions, or both. Jennifer said that there may be a lot of information held by insurance carriers, when it comes to medication data. Tom added that the difference between what is ordered, and what is picked up is important to understand, and ideally the best solution will help providers understand all of these gaps. Nitu added that we cannot rely on PBMs as the only source of information, as there are some challenges. Nitu thinks we should look at what is available from Surescripts as well. Surescripts only contains data on dispensed medications. Jennifer added that this group may play a role in defining the groups where data currently exists and help to identify different ways to get data from each group and segmenting the work this way. Nitu and Tom said agree that this could be a good approach.

Michael asked Dr. Phil Smith if there are any states that stand out as shining examples of the single source of truth. Dr. Smith said that he has not seen the any other states use the approach that Connecticut is using, which is exciting. He added that The Blue Ox Network in Delaware is one example of a successful private group. He believes what is being done in Connecticut could become a model that is replicated by other states in the future. Sean Jeffery asked if Dr. Smith has any thoughts about potential pitfalls. Dr. Smith said that his main issue is the word "medication reconciliation" because it is a work-around to a broken process. He does not think everyone should be building their own medication history databases. Sean thinks Connecticut is in a good position to break down some of these siloes. Jennifer thinks there are potential legal issues around the ownership and access to the central medication database, as well as the data integrity.

Tom said there are other Sub-committees that will contribute to this conversation. The Technology group should be looking at what is possible, and we can hand off policy questions to the other Sub-committees. Bruce agrees that we will need some guard rails to our work and create a scaled-down project charter. Michael agreed and asked members to review the project charter goals and determine which items should be addressed by this Sub-committee. Dr. Phil Smith and Tom Agresta both agreed that the group should take some time to define terminology (goal #2). The Sub-committee also believe that goals #4, #5, #6, #8 and #9 will be important. None of the goals are completely specific to technology, however many will need to involve the technology Sub-committee at some level. Michael explained there are sub-bullets to each goal that can be reviewed at the next meeting in order to avoid duplication of work between the Sub-committees.

5.	Next Steps and Adjournment	Sarju Shah	3:55 PM			
	The Sub-committee agreed that the next meeting will of will be done around existing technology and best pract committee will begin to meet on a monthly basis until t delivered to the larger MRP Work Group. Bruce thanke great discussion.	ices. Following the February meeting, the here and of May, when recommendations	e Sub- will be			

Sarju will work on scheduling the next meeting for the end of February and will research the possibility of creating a shared, digital collaboration space.

Upcoming Meeting Schedule: Future meetings will be scheduled at a later date Meeting information is located at: <u>https://portal.ct.gov/OHS/HIT-Work-Groups/Medication-Reconciliation-and-</u> Polypharmacy-Work-Group